Zalcitabine pharmacokinetics

In a study in 10 HIV-positive patients, zalcitabine 750 micrograms every 8 hours increased the AUC of oral ganciclovir 1 g three times daily by 22%. There was no change in zalcitabine pharmacokinetics. There were no serious or severe adverse events attributed to the combination. ... [Pg.798]

Children - Limited pharmacokinetic data have been reported for 5 HIV-positive children using doses of 0.03 and 0.04 mg/kg administered orally every 6 hours. The mean bioavailability of zalcitabine in this study was 54% and mean apparent systemic clearance was 150 mL/min/m. ... [Pg.1863]

Saag MS, Sommadossi JP, Rainey D, Myers M, Cort S, Hall D, et al. A pharmacokinetic and antiretroviral activity study of nevirapine in combination with zidovudine plus zalcitabine (ZDV/ddC), zidovudine plus didanosine (ZDV/ddI), or didanosine (ddl) Alone. In The First National Conference on Human Retroviruses and Related Infections, Washington D.C., 1993 102. [Pg.78]

Pharmacokinetics and clinical use Zalcitabine has high oral bioavailability. Dosage adjustment is needed in patients with renal insufficiency. Zalcitabine is always used in combination with other anti-HIV drugs. [Pg.431]

No pharmacokinetic interactions occur between foscarnet and di-danosine, zalcitabine or zidovudine. The UK manufacturer does not recommend the concurrent use of lamivudine and foscarnet... [Pg.778]

Intravenous foscarnet 90 mg/kg every 12 hours and oral zalcitabine 750 micrograms every 8 hours were given to 12 HIV-positive subjects for 2 days. There were no clinically significant alterations in the pharmacokinetics of either drug. However, the manufacturers of zalcitabine suggested that the concurrent use of zalcitabine and foscarnet should be well monitored, because foscarnet may possibly decrease the renal elearanee of the zalcitabine, thereby increasing its serum levels and its toxicity, particularly peripheral neuropathy. The antiretroviral effects of foscarnet and zalcitabine were synergistic. ... [Pg.778]

Hivid (Zalcitabine). Roche Pharmaceuticals. US Prescribing information, September 2002. Aweeka FT, Gambertoglio JG, van der Horst C, Raasch R, Jacobson MA. Pharmacokinetics of concomitantiy administered foscarnet and zidovudine for treatment of human immunodeficiency virus irifection (AIDS clinical trials group protocol 053). Antimicrob Agents Chem-other(l992)36,1773-8. [Pg.778]

MacGregor TR, Lamson MJ, C 1, Pav JW, Saag MS, Elvin AT, Scmmadossi J-P, Myers M, Keims JJ. Steady state pharmacokinetics of nevirapine, didanosine, zalcitabine, and zidovudine combination therapy in HIV-1 positive patients. PharmRes (1995) 12 (9 Si pl), S-101. [Pg.785]

Aluminium/magnesium hydroxide caused a 25% reduction in the bioavailability of zalcitabine. Antacids would not be expected to have any additional pharmacokinetic effect on buffered didanos-ine preparations. [Pg.792]

Massarella JW, Holazo AA, Koss-Twardy S, Min B, Smith B, Nazareno LA. The effects of cimetidine and Maalox on the pharmacokinetics of zalcitabine in HIV-positive patients. PharmRes ( 994) 11 (lOSuppl), S-415. [Pg.792]

A study in 12 HIV-positive patients found that when zalcitabine 1.5 mg three times daily was given with isoniazid 300 mg daily the pharmacokinetics of the zalcitabine remained unchanged but the clearance of the isoniazid was approximately doubled. The UK manufacturer of zalcitabine recommended caution with the combination because of the possibility of an increased risk of peripheral neuropathy the US manufacturer recommended that the combination should be avoided where possible. ... [Pg.793]

Lee BL, Tauber MG, Chambers HF, GambertogUo J, Delahunty T. The effect of zalcitabine on the pharmacokinetics of isoniazid in HIV-infected patients. Intend Corf Antimicrob... [Pg.793]

There is no pharmacokinetic interaction between stavudine and fluconazole. No interaction would be expected with other similar NRTIs such as lamivudine and zalcitabine (see Antivirals , (p.772)). [Pg.794]

Ganciclovir does not appear to alter the pharmacokinetics of stavudine or zalcitabine. Zalcitabine increased ganciclovir levels to a minor extent, although this is probably not clinically important. [Pg.799]

Jung D, AbdelHameed MH, Teitelbaum P, Dorr A, Griffy K. The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV-and CMV-seropositive patients. J Clin Pharmacol (1999) 39, 505-12. [Pg.799]

A 7-day course of clarithromycin 500 mg twice daily was given to 12 HIV-positive subjects already taking zalcitabine. The addition of clarithromycin caused no change to the pharmacokinetics of zalcitabine. ... [Pg.800]

The manufacturer of zalcitabine noted that there is no pharmacokinetic interaction with saquinavir. They stated that pharmacokinetic interactions with protease inhibitors would not be expected, since zalcitabine is mainly excreted unchanged in the urine. ... [Pg.805]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...